Phenylpropanoids and Aldehydes Group

These substances were identified for action under the Chemicals Management Plan (CMP). The assessment focuses on 12 substances, referred to collectively under the CMP as the Phenylpropanoids and Aldehydes Group, which are a part of the larger Terpenes and Terpenoids Group.

• Summary of publications
• Timelines
• Background

Summary of publications

Substance group	Subgroup	CAS RN	Common name	DSL name	Draft assessment	Risk management scope	Proposed conclusion on section 64 criteria	Follow-up activities
Phenylpropanoids and Aldehydes Group	N/A - individual	8006-78-8Footnote a	Bay oil	Oils, bay	HTML	HTML	Meets one or more of the criteria	Refer to the risk management scope
	N/A - individual	8016-88-4Footnote a	Tarragon oil	Oils, tarragon
	1	8022-96-6Footnote a	Jasmine oil	Oils, jasmine
	1	8024-43-9Footnote a	Perfumes and essences of jasmin	Perfumes and essences, jasmin
	N/A - individual	8024-08-6Footnote a	Violet oil	Oils, violet
	2	80-54-6	Lilial	Benzenepropanol, 4-(1,1-dimethylethyl)-α-methyl-
	2	91-51-0	Verdantiol	Benzoic acid, 2-[[3-[4-(1,1-dimethylethyl)phenyl]-2-methylpropylidene]amino]-, methyl ester		None	Does not meet	Under consideration
	2	37677-14-8	Myrac-aldehyde	3-Cyclohexene-1-carboxaldehyde, 4-(4-methyl-3-pentenyl)-
	2	52474-60-9	Myrmac-aldehyde	3-Cyclohexene-1-carboxaldehyde, 1-methyl-3-(4-methyl-3-pentenyl)-
	2	52475-86-2	Myrmac-carboxaldehyde	3-Cyclohexene-1-carboxaldehyde, 1-methyl-4-(4-methyl-3-pentenyl)-
	2	65405-84-7	Cetonal	Cyclohexenebutanal, α,2,2,6-tetramethyl-
	2	66327-54-6	Vernaldehyde	3-Cyclohexene-1-carboxaldehyde, 1-methyl-4-(4-methylpentyl)-
a This substances is a UVCB (substance of unknown or variable composition, complex reaction products, or biological materials). Return to footnote a referrer

Timelines

Date	Activity
February 2025	Anticipated publication of the final assessment and proposed risk management approach.
February 3, 2024	Publication and start of 60-day public comment period on the Draft Assessment for Terpenes and Terpenoids Phenylpropanoids and Aldehydes Group and the Risk Management Scope for Terpenes and Terpenoids Phenylpropanoids and Aldehydes Group. The related notice was published in the Canada Gazette, Part I: Vol. 158, No. 5.

Background

The assessment focuses on 12 substances referred to as the Phenylpropanoids and Aldehydes Group. The human health risk assessment addressed 9 of the 12 substances under 2 subgroups, due to similarities in chemical structure, properties, or toxicity, while the remaining 3 substances were addressed individually. The ecological risks of substances in this group were characterized using the Ecological Risk Classification of Organic Substances (ERC) Approach. These 12 substances are a part of a larger group of 76 substances referred to collectively under the CMP as the Terpenes and Terpenoids Group.

Three of these 76 substances were subsequently determined to be of low concern to both human health and the environment through other approaches. The conclusion for CAS RN 25428-43-7 is provided in the Final Screening Assessment for the Rapid Screening of Substances with Limited General Population Exposure. Conclusions for CAS RNs 29350-73-0 and 68916-97-2 are provided in the Final Screening Assessment of Substances Identified as Being of Low Concern using the Ecological Risk Classification of Organic Substances and the Threshold of Toxicological Concern (TTC)-based Approach for Certain Substances.

Fifteen of these 76 substances (CAS RNs 80-56-8, 1113-21-9, 8000-46-2, 8002-09-3, 8006-64-2, 8007-01-0, 8007-02-1, 8008-31-9, 8008-52-4, 8008-57-9, 8014-19-5, 8015-77-8, 8016-85-1, 8021-28-1 and 9005-90-7) were assessed as a part of the Acyclic, Monocyclic, and Bicyclic Monoterpenes Group.

Sixteen of these 76 substances (CAS RNs 495-62-5, 8001-61-4, 8007-0-7, 17627-44-0, 65113-99-7, 107898-54-4, 87-44-5, 88-84-6, 3691-12-1, 4630-07-3, 68917-29-3, 489-86-1, 639-99-6, 22451-73-6, 489-84-9 and 8006-87-9) were assessed as a part of the Monocyclic and Bicyclic Sesquiterpenes Group.

Decisions on the remaining 30 substances will be communicated in separate risk assessments.